Archive

HIGHLIGHTS

 
LSP co-leads €60 million Series A financing in Muna Therapeutics
Proceeds dedicated to the development of novel small molecule therapeutics for neurodegenerative diseases Innovative drug discovery platf[...]
 
LSP invests in $70 million Series A financing of Xilis
to advance cancer diagnostic and drug discovery and development platform leveraging proprietary MicroOrganoSphere technology   Xilis[...]
 
ONWARD Receives FDA Breakthrough Device Designation for ARC-IM for Blood Pressure
and Trunk Control in Spinal Cord Injury   Third Breakthrough Device Designation Awarded to the Company for Innovative Technologies   [...]
 
eTheRNA and VUB expand strategic collaboration to engineer next generation mRNA ...
  Extension to proven TriMix® adjuvant technology intended to boost dendritic cell activation       eTheRNA immunotherapie[...]
 
THE APPROVAL OF ADUCANUMAB FOR ALZHEIMER'S
WILL BENEFIT THE DEVELOPMENT OF OTHER DEMENTIA DRUGS GREATLY   The LSP Dementia Fund's view on the recent FDA approval   Amst[...]
 
LSP portfolio company binx health raises $104 million
from blue chip investor syndicate to expand its groundbreaking digital business model   Financing led by OrbiMed, and includes Arrowma[...]
 
LSP leads € 20 million Series A equity financing round in Innovative Molecules
Proceeds dedicated to advance Herpes simplex treatment IM-250 to Phase II IM-250 demonstrates unprecedented impact on viral reservoir in [...]
 
LSP Portfolio Company Artios Pharma Announces Collaboration with Novartis to Create...
Novartis to leverage Artios’ discovery platform to identify DDR targets for use with Novartis’ proprietary radioligand therapies. [...]
 
LSP ANNOUNCES CLOSING OF UPSIZED $120 MILLION NASDAQ IPO
OF EUROPEAN BIOTECH ACQUISITION CORP (EBAC) TARGETING EUROPEAN BIOTECH   EBAC IS THE FIRST HEALTHCARE SPAC TO EXCLUSIVELY FOCUS ON  E[...]
 
LSP’s portfolio company Simplify Medical acquired by NuVasive
Amsterdam, the Netherlands, February 25, 2021 – LSP, a leading European investor in health care, announces that NuVasive, Inc. (NASDAQ: NUVA), th[...]

2021


LSP co-leads €60 million Series A financing in Muna Therapeutics
Proceeds dedicated to the development of novel small molecule therapeutics for neurodegenerative diseases Innovative drug discovery platform leveraging insights from novel targets and pathways, resilience to [...]
LSP invests in $70 million Series A financing of Xilis
to advance cancer diagnostic and drug discovery and development platform leveraging proprietary MicroOrganoSphere technology   Xilis’ MicroOrganoSphere™ (MOS) technology generates thousands of miniatu [...]
ONWARD Receives FDA Breakthrough Device Designation for ARC-IM for Blood Pressure
and Trunk Control in Spinal Cord Injury   Third Breakthrough Device Designation Awarded to the Company for Innovative Technologies   EINDHOVEN, Netherlands & LAUSANNE, Switzerland, June 17, 2021--(BU [...]
eTheRNA and VUB expand strategic collaboration to engineer next generation mRNA therapeutics with TetraMix®
  Extension to proven TriMix® adjuvant technology intended to boost dendritic cell activation       eTheRNA immunotherapies NV (‘eTheRNA’, Niel, Belgium), a clinical-stage company developi [...]
LSP leads € 20 million Series A equity financing round in Innovative Molecules
Proceeds dedicated to advance Herpes simplex treatment IM-250 to Phase II IM-250 demonstrates unprecedented impact on viral reservoir in preclinical studies   Munich, Germany, June 9, 2021 - LSP, [...]
THE APPROVAL OF ADUCANUMAB FOR ALZHEIMER'S
WILL BENEFIT THE DEVELOPMENT OF OTHER DEMENTIA DRUGS GREATLY   The LSP Dementia Fund's view on the recent FDA approval   Amsterdam, The Netherlands, June 8, 2021 – Yesterday the U.S. FDA (Food [...]


2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to news overview
Follow us

Archive

HIGHLIGHTS

 
LSP co-leads €60 million Series A financing in Muna Therapeutics
Proceeds dedicated to the development of novel small molecule therapeutics for neurodegenerative diseases Innovative drug discovery platform leveraging insights from novel targets and pathways, resilience to[...]
 
LSP invests in $70 million Series A financing of Xilis
to advance cancer diagnostic and drug discovery and development platform leveraging proprietary MicroOrganoSphere technology   Xilis’ MicroOrganoSphere™ (MOS) technology generates thousands of miniatu[...]
 
ONWARD Receives FDA Breakthrough Device Designation for ARC-IM for Blood Pressure
and Trunk Control in Spinal Cord Injury   Third Breakthrough Device Designation Awarded to the Company for Innovative Technologies   EINDHOVEN, Netherlands & LAUSANNE, Switzerland, June 17, 2021--(BU[...]
 
eTheRNA and VUB expand strategic collaboration to engineer next generation mRNA therapeutics with TetraMix®
  Extension to proven TriMix® adjuvant technology intended to boost dendritic cell activation       eTheRNA immunotherapies NV (‘eTheRNA’, Niel, Belgium), a clinical-stage company developi[...]
 
THE APPROVAL OF ADUCANUMAB FOR ALZHEIMER'S
WILL BENEFIT THE DEVELOPMENT OF OTHER DEMENTIA DRUGS GREATLY   The LSP Dementia Fund's view on the recent FDA approval   Amsterdam, The Netherlands, June 8, 2021 – Yesterday the U.S. FDA (Food [...]
 
LSP portfolio company binx health raises $104 million
from blue chip investor syndicate to expand its groundbreaking digital business model   Financing led by OrbiMed, and includes Arrowmark Partners, Hildred Capital Management, Alta Life Sciences and Parian[...]
 
LSP leads € 20 million Series A equity financing round in Innovative Molecules
Proceeds dedicated to advance Herpes simplex treatment IM-250 to Phase II IM-250 demonstrates unprecedented impact on viral reservoir in preclinical studies   Munich, Germany, June 9, 2021 - LSP, [...]
 
LSP Portfolio Company Artios Pharma Announces Collaboration with Novartis to Create New Cancer Therapies
Novartis to leverage Artios’ discovery platform to identify DDR targets for use with Novartis’ proprietary radioligand therapies. Artios to receive US$20 million up-front payment in addition to near[...]
 
LSP ANNOUNCES CLOSING OF UPSIZED $120 MILLION NASDAQ IPO
OF EUROPEAN BIOTECH ACQUISITION CORP (EBAC) TARGETING EUROPEAN BIOTECH   EBAC IS THE FIRST HEALTHCARE SPAC TO EXCLUSIVELY FOCUS ON  EUROPEAN BIOTECH EDUARDO BRAVO TO JOIN LSP AS A PARTNER AND BECOM[...]
 
LSP’s portfolio company Simplify Medical acquired by NuVasive
Amsterdam, the Netherlands, February 25, 2021 – LSP, a leading European investor in health care, announces that NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine[...]

2021


LSP co-leads €60 million Series A financing in Muna Therapeutics
Proceeds dedicated to the development of novel small molecule therapeutics for neurodegenerative diseases Innovative drug discovery platform leveraging insights from novel targets and pathways, resilience to [...]
LSP invests in $70 million Series A financing of Xilis
to advance cancer diagnostic and drug discovery and development platform leveraging proprietary MicroOrganoSphere technology   Xilis’ MicroOrganoSphere™ (MOS) technology generates thousands of miniatu [...]
ONWARD Receives FDA Breakthrough Device Designation for ARC-IM for Blood Pressure
and Trunk Control in Spinal Cord Injury   Third Breakthrough Device Designation Awarded to the Company for Innovative Technologies   EINDHOVEN, Netherlands & LAUSANNE, Switzerland, June 17, 2021--(BU [...]
eTheRNA and VUB expand strategic collaboration to engineer next generation mRNA therapeutics with TetraMix®
  Extension to proven TriMix® adjuvant technology intended to boost dendritic cell activation       eTheRNA immunotherapies NV (‘eTheRNA’, Niel, Belgium), a clinical-stage company developi [...]
LSP leads € 20 million Series A equity financing round in Innovative Molecules
Proceeds dedicated to advance Herpes simplex treatment IM-250 to Phase II IM-250 demonstrates unprecedented impact on viral reservoir in preclinical studies   Munich, Germany, June 9, 2021 - LSP, [...]
THE APPROVAL OF ADUCANUMAB FOR ALZHEIMER'S
WILL BENEFIT THE DEVELOPMENT OF OTHER DEMENTIA DRUGS GREATLY   The LSP Dementia Fund's view on the recent FDA approval   Amsterdam, The Netherlands, June 8, 2021 – Yesterday the U.S. FDA (Food [...]


2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to news overview